"Lakeside Holding, a US-based cross-border supply chain solution provider with a unique focus on the Asia-Pacific market has announced that Hupan Pharmaceutical has signed a Sales Agreement with Sinopharm Holding Hubei New Special Medicine Co., a subsidiary of Sinopharm Group, based in China.
The agreement, valued at approximately RMB 11.0 million (approximately $1.5 million), is effective from January 1, 2025, through the end of the year and involves the sale and delivery of critical medicines, including Sodium Bicarbonate, Glucose, and Glucose Sodium Chloride.
This agreement follows the partnership with Sinopharm Group announced last month focusing on essential medicine storage, transportation, and logistics services. These achievements reflect Hupan Pharmaceutical's expanding role as a reliable provider of pharmaceutical solutions in China.
"We are excited to strengthen our relationship with Sinopharm Group further, a leading global player in the healthcare industry," said Lan Su, COO of Lakeside Holding Limited. "This agreement demonstrates our capabilities in delivering high-quality pharmaceutical products, ensuring reliable supplies of essential medicines. We remain committed to broadening our portfolio and expanding our market reach, enhancing our role as a trusted pharmaceutical solutions provider."
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions! Learn More!